Awonabee...I own both NSTK and PTIE and this is the one complaint I have about Remi. He may have a great stable of drugs, but he can only prove it by doing a deal. The NSTK drug is going to accellerated as are other compounds at other drug and biotech companies. I think the longer Remi waits the market is going to feel he can't make a deal and the large drug companies have no interest. With the Phase II Oxytrex data the stock languishes.
The great arbiter of value is the market, and unless I am missing something, the market may be having a tough time believing the company's story line. I am willing to give my investment time, but I do not think that is a luxury Remi and the company have. All you need is a major announcement by a big drug operation that they have a great non-addictive oxycontin type drug. The risk of hubris and ego.
Managed to sell half my holding above $6.00 today. Nice at NSTK today !!! well done, don't own it but tempted by their PYY candidate.
I fear the widespread sell-off may continue into next week. We'v ranged from being over sold back in Feb/Mar to over bought in Aug/Sep. There is now a chance we may well see the othe end of the pendulum yet again. Especially for companies without earnings support.
Thanks...NSTK pyy 3-36 could be a huge drug. The CEO is pretty smart and the supporting cast great. Nasal drug delivery is a bit of a hard sell but for injectable drugs it could be a hit. They had amazing Phase I results on pyy. Only company with a potential blockbuster weight loss drug in the clinic. Story you should follow.